{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T23:13:14Z","timestamp":1762125194242,"version":"3.40.5"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ijantimicag.2016.12.021","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T20:46:50Z","timestamp":1488833210000},"page":"650-654","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation"],"prefix":"10.1016","volume":"49","author":[{"given":"Benjamin J.","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonia N.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila K.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane Y.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irfana Y.","family":"Lakada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elise M.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktorija O.","family":"Barr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Postelnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah H.","family":"Sutton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa R.","family":"Zembower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Bolon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc H.","family":"Scheetz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0018-5434","authenticated-orcid":false,"given":"Nathaniel J.","family":"Rhodes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0010","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1093\/cid\/ciu410","article-title":"Staphylococcus aureus bacteremia at 5 US academic medical centers, 2008\u20132011: significant geographic variation in community-onset infections","volume":"59","author":"David","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0015","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1017\/ice.2015.213","article-title":"Evolving epidemiology of Staphylococcus aureus bacteremia","volume":"36","author":"Rhee","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0020","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1093\/cid\/ciu301","article-title":"Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting","volume":"59","author":"Youngster","year":"2014","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0025","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1161\/CIR.0000000000000296","article-title":"Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association","volume":"132","author":"Baddour","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0030","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1002\/phar.1491","article-title":"Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance","volume":"34","author":"Rybak","year":"2014","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0035","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/phar.1641","article-title":"Dalbavancin and oritavancin: an innovative approach to the treatment of Gram-positive infections","volume":"35","author":"Roberts","year":"2015","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0040","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1128\/AAC.02800-14","article-title":"Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus","volume":"58","author":"Li","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0045","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/j.ijantimicag.2014.09.002","article-title":"Antistaphylococcal penicillins versus cephalosporins for definitive treatment of meticillin-susceptible Staphylococcus aureus bacteraemia: a systematic review and meta-analysis","volume":"44","author":"Vardakas","year":"2014","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0050","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1093\/jac\/dku560","article-title":"Comparative effectiveness of cefazolin versus cloxacillin as definitive antibiotic therapy for MSSA bacteraemia: results from a large multicentre cohort study","volume":"70","author":"Bai","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0055","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1093\/cid\/civ308","article-title":"Comparative effectiveness of \u03b2-lactams versus vancomycin for treatment of methicillin-susceptible Staphylococcus aureus bloodstream infections among 122 hospitals","volume":"61","author":"McDanel","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0060","doi-asserted-by":"publisher","first-page":"5232","DOI":"10.1128\/AAC.04677-14","article-title":"Treatment outcomes with cefazolin versus oxacillin for deep-seated methicillin-susceptible Staphylococcus aureus bloodstream infections","volume":"59","author":"Rao","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0065","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.1128\/AAC.00485-11","article-title":"Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?","volume":"55","author":"Lee","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0070","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1111\/j.1469-0691.2010.03425.x","article-title":"Are all \u03b2-lactams similarly effective in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia?","volume":"17","author":"Paul","year":"2011","journal-title":"Clin Microbiol Infect"},{"year":"2014","series-title":"Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement","author":"Clinical and Laboratory Standards Institute","key":"10.1016\/j.ijantimicag.2016.12.021_bib0075"},{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0080","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1086\/518751","article-title":"Controlling for severity of illness in assessment of the association between antimicrobial-resistant infection and mortality: impact of calculation of Acute Physiology and Chronic Health Evaluation (APACHE) II scores at different time points","volume":"28","author":"Hamilton","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0085","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1086\/591453","article-title":"Controlling for severity of illness in outcome studies involving infectious diseases: impact of measurement at different time points","volume":"29","author":"Thom","year":"2008","journal-title":"Infect Control Hosp Epidemiol"},{"year":"2015","series-title":"OXACILLIN\u00ae package insert","author":"Sagent Pharmaceuticals","key":"10.1016\/j.ijantimicag.2016.12.021_bib0090"},{"year":"2016","series-title":"CEFAZOLIN\u00ae package insert","author":"Hospira, Inc.","key":"10.1016\/j.ijantimicag.2016.12.021_bib0095"},{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0100","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/MD.0b013e3181b8fccb","article-title":"Infectious diseases consultation lowers mortality from Staphylococcus aureus bacteremia","volume":"88","author":"Lahey","year":"2009","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijantimicag.2016.12.021_bib0105","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1007\/s10096-012-1585-y","article-title":"Formal infectious diseases consultation is associated with decreased mortality in Staphylococcus aureus bacteraemia","volume":"31","author":"Robinson","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917300791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,3]],"date-time":"2018-09-03T16:25:39Z","timestamp":1535991939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917300791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S0924857917300791"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.12.021","relation":{},"ISSN":["0924-8579"],"issn-type":[{"type":"print","value":"0924-8579"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.12.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}